Tetra Radar · FDA Approvals · Decision date

pelacarsen: FDA decision date

Royalty Pharma plc (RPRX) · 23 April 2027

In July 2026, Pharvaris announced that the FDA accepted its New Drug Application (NDA) for deucrictibant immediate-release for the on-demand treatment of HAE attacks and assigned a Prescription Drug User Fee Act (PDUFA) date of April 23, 2027. pelacarsen.

Source: 8-K of 4 November 2026

The decision is pending.

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.